Updated Jul 16, 2026 · Last SEC filing 2026-07-14
Eton Pharmaceuticals, Inc. (ETON) has filed 8 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-14. 5 Form 8-K material event filings were reported by ETON in the last 90 days. 7 Form 144 notices of proposed sale were filed for ETON stock. InsiderAlpha tracks every ETON SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001710340 |
|---|
| Form 4 filings (90d) | 8 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 7 |
| Latest Form 4 filing | 2026-07-14 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| BRYNJELSEN SEAN | President & CEO | M — Option exercise | 200.0K | $1.37 | $274K | SEC | |
| Krempa David | Chief Business Officer | M — Option exercise | 10.0K | — | — | SEC | |
| BRYNJELSEN SEAN | President & CEO | M — Option exercise | 27.5K | — | — | SEC | |
| Opaleye Management Inc. | 10% Owner | S — Open-market sale | 20.0K | $38.37 | $767K | SEC | |
| Opaleye Management Inc. | 10% Owner | S — Open-market sale | 6.7K | $38.37 | $257K | SEC | |
| Opaleye Management Inc. | 10% Owner | S — Open-market sale | 10.0K | $38.00 | $380K | SEC | |
| Opaleye Management Inc. | 10% Owner | S — Open-market sale | 25.0K | $37.39 | $935K | SEC | |
| Opaleye Management Inc. | 10% Owner | S — Open-market sale | 65.0K | $37.39 | $2.43M | SEC | |
| Adams Jennifer McKie | Director | S — Open-market sale | 50.0K | $32.48 | $1.62M | SEC | |
| Adams Jennifer McKie | Director | M — Option exercise | 50.0K | $3.78 | $189K | SEC | |
| BRYNJELSEN SEAN | President & CEO | S — Open-market sale | 148 | $32.67 | $5K | SEC | |
| BRYNJELSEN SEAN | President & CEO | S — Open-market sale | 119.9K | $31.88 | $3.82M | SEC | |
| Krempa David | Chief Business Officer | M — Option exercise | 7.2K | $3.58 | $26K | SEC | |
| Krempa David | Chief Business Officer | M — Option exercise | 12.5K | $1.37 | $17K | SEC | |
| Krempa David | Chief Business Officer | S — Open-market sale | 19.7K | $31.47 | $619K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Eton Pharmaceuticals, Inc. (ETON). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Krempa David | 18 | $3.43M |
| BRYNJELSEN SEAN | 6 | $4.10M |
| Opaleye Management Inc. | 5 | $4.77M |
| RIEDEL NORBERT G | 4 | $261K |
| Adams Jennifer McKie | 3 | $1.81M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ETON insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ETON dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.